Conversion Effects of PD-1 Antibody Camrelizumab Combined With Nab-POF Regimen Chemotherpy in Patients With Initially Unresectable Locally Advanced or Limited Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma：FDZL-GC001 Trial
Clinical trial NCT04510064 · COMPLETED
Trial details
- NCT number
- NCT04510064
- Sponsor
- Fudan University
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-01-06
- Primary completion
- 2024-07-31
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.